PDCD1 and neoplasm: Tumor-bearing mice received a daily intraperitoneal injection (i.p.)of SFN only (SFN only), or meso CAR-T cell infusion with exogenous SFN administration (CAR-T + SFN), or anti-PD-1 treatment (CAR-T + anti-PD-1) (Fig. 5A).